44 related articles for article (PubMed ID: 2140788)
1. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.
Waters CA; Schimke PA; Snider CE; Itoh K; Smith KA; Nichols JC; Strom TB; Murphy JR
Eur J Immunol; 1990 Apr; 20(4):785-91. PubMed ID: 2140788
[TBL] [Abstract][Full Text] [Related]
2. Innate Lymphoid Cells and Natural Killer Cells in Bacterial Infections: Function, Dysregulation, and Therapeutic Targets.
Elemam NM; Ramakrishnan RK; Hundt JE; Halwani R; Maghazachi AA; Hamid Q
Front Cell Infect Microbiol; 2021; 11():733564. PubMed ID: 34804991
[TBL] [Abstract][Full Text] [Related]
3. Targeted Diphtheria Toxin-Based Therapy: A Review Article.
Shafiee F; Aucoin MG; Jahanian-Najafabadi A
Front Microbiol; 2019; 10():2340. PubMed ID: 31681205
[TBL] [Abstract][Full Text] [Related]
4. Functional paralysis of human natural killer cells by alphaherpesviruses.
Campbell TM; McSharry BP; Steain M; Russell TA; Tscharke DC; Kennedy JJ; Slobedman B; Abendroth A
PLoS Pathog; 2019 Jun; 15(6):e1007784. PubMed ID: 31194857
[TBL] [Abstract][Full Text] [Related]
5. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
Oka T; Miyagaki T
Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
[TBL] [Abstract][Full Text] [Related]
6. DAB
Bhopale MK; Hilliard B; Constantinescu CS; Phillips SM; Rostami A
Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):318-329. PubMed ID: 28929835
[TBL] [Abstract][Full Text] [Related]
7. Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.
Chang JH; Jiang Y; Pillarisetty VG
Medicine (Baltimore); 2016 Dec; 95(49):e5541. PubMed ID: 27930550
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
9. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
Morse MA; Hobeika AC; Osada T; Serra D; Niedzwiecki D; Lyerly HK; Clay TM
Blood; 2008 Aug; 112(3):610-8. PubMed ID: 18519811
[TBL] [Abstract][Full Text] [Related]
10. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
Powell DJ; Attia P; Ghetie V; Schindler J; Vitetta ES; Rosenberg SA
J Immunother; 2008; 31(2):189-98. PubMed ID: 18481388
[TBL] [Abstract][Full Text] [Related]
11. Optimization of protein therapies by polymer-conjugation as an effective DDS.
Shibata H; Nakagawa S; Tsutsumi Y
Molecules; 2005 Jan; 10(1):162-80. PubMed ID: 18007284
[TBL] [Abstract][Full Text] [Related]
12. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
[TBL] [Abstract][Full Text] [Related]
13. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
Attia P; Powell DJ; Maker AV; Kreitman RJ; Pastan I; Rosenberg SA
J Immunother; 2006; 29(2):208-14. PubMed ID: 16531821
[TBL] [Abstract][Full Text] [Related]
14. The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex.
Ratts R; Zeng H; Berg EA; Blue C; McComb ME; Costello CE; vanderSpek JC; Murphy JR
J Cell Biol; 2003 Mar; 160(7):1139-50. PubMed ID: 12668662
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human NK cell function by valinomycin, a toxin from Streptomyces griseus in indoor air.
Paananen A; Mikkola R; Sareneva T; Matikainen S; Andersson M; Julkunen I; Salkinoja-Salonen MS; Timonen T
Infect Immun; 2000 Jan; 68(1):165-9. PubMed ID: 10603383
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.
Salard D; Kuzel TM; Samuelson E; Rosen S; Bakouche O
J Clin Immunol; 1998 May; 18(3):223-34. PubMed ID: 9624582
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
[TBL] [Abstract][Full Text] [Related]
18. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor.
Pickering JG; Bacha PA; Weir L; Jekanowski J; Nichols JC; Isner JM
J Clin Invest; 1993 Feb; 91(2):724-9. PubMed ID: 8432873
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.
vanderSpek J; Cosenza L; Woodworth T; Nichols JC; Murphy JR
Mol Cell Biochem; 1994 Sep; 138(1-2):151-6. PubMed ID: 7898459
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.
Bacha P; Forte S; Kassam N; Thomas J; Akiyoshi D; Waters C; Nichols J; Rosenblum M
Cancer Chemother Pharmacol; 1990; 26(6):409-14. PubMed ID: 2225311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
